Molecular structure of MY-5445, CAS Number: 78351-75-4
MY-5445 (CAS 78351-75-4)
See product citations (2)
Application:
MY-5445 is a selective cGMP phosphodiesterase inhibitor
CAS Number:
78351-75-4
Purity:
99%
Molecular Weight:
331.8
Molecular Formula:
C20H14ClN3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
MY-5445, also known as 1-(3-chloroanilino)-4-phenylphthalazine, is an inhibitor of platelet aggregation via an increase in cyclic GMP. Mechanistic studies suggest that this compound affects cyclic GMP phosphodiesterase, therefore preventing metabolism of cyclic GMP in platelets. Experiments show that MY-5445 does not have any impact on cyclic AMP content, and has the potential to cause relaxation of rat aorta.
MY-5445 (CAS 78351-75-4) References
- cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo. | Xu, HL., et al. 2004. Am J Physiol Heart Circ Physiol. 287: H2501-9. PMID: 15271668
- Cyclic nucleotides and neuroblastoma differentiation. | Messina, E., et al. 2004. Nucleosides Nucleotides Nucleic Acids. 23: 1551-4. PMID: 15571296
- Up-regulation of microglial CD11b expression by nitric oxide. | Roy, A., et al. 2006. J Biol Chem. 281: 14971-80. PMID: 16551637
- Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. | Nagendran, J., et al. 2007. Circulation. 116: 238-48. PMID: 17606845
- Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. | Durate, ID., et al. 1990. Eur J Pharmacol. 186: 289-93. PMID: 1981187
- Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. | Souness, JE., et al. 1989. Br J Pharmacol. 98: 725-34. PMID: 2480168
- Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. | Bollenbach, M., et al. 2019. Eur J Med Chem. 177: 269-290. PMID: 31158744
- MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. | Wu, CP., et al. 2020. Am J Cancer Res. 10: 164-178. PMID: 32064159
- STIMULATION OF THE CYCLIC AMP/GMP SIGNALLING ENHANCES THE RELAXATION OF ISOLATED HUMAN DETRUSOR SMOOTH MUSCLE ACHIEVED BY PHOSPHODIESTERASE INHIBITORS. | Rahardjo, HE., et al. 2021. Georgian Med News. 7-12. PMID: 34103422
- Suppression of Proliferation of Human Glioblastoma Cells by Combined Phosphodiesterase and Multidrug Resistance-Associated Protein 1 Inhibition. | Kopanitsa, L., et al. 2021. Int J Mol Sci. 22: PMID: 34575827
- Antiallodynic action of phosphodiesterase inhibitors in a mouse model of peripheral nerve injury. | Megat, S., et al. 2022. Neuropharmacology. 205: 108909. PMID: 34875284
- Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. | Hagiwara, M., et al. 1984. J Pharmacol Exp Ther. 228: 467-71. PMID: 6141286
- Inhibitory effects of natriuretic peptides on vasopressin neurons mediated through cGMP and cGMP-dependent protein kinase in vitro. | Akamatsu, N., et al. 1993. J Neuroendocrinol. 5: 517-22. PMID: 8680419
Inhibitor of:
PDE, and PDE1A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MY-5445, 10 mg | sc-201195 | 10 mg | $153.00 |